CN110452276B - Strawberry plant extract, extraction method and application thereof in immunoregulation and anti-inflammation - Google Patents

Strawberry plant extract, extraction method and application thereof in immunoregulation and anti-inflammation Download PDF

Info

Publication number
CN110452276B
CN110452276B CN201910373148.2A CN201910373148A CN110452276B CN 110452276 B CN110452276 B CN 110452276B CN 201910373148 A CN201910373148 A CN 201910373148A CN 110452276 B CN110452276 B CN 110452276B
Authority
CN
China
Prior art keywords
strawberry
fragaria
plant
period
strawberry plant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910373148.2A
Other languages
Chinese (zh)
Other versions
CN110452276A (en
Inventor
林汶锋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Singapore Lihui Co ltd
Original Assignee
Singapore Lihui Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Lihui Co ltd filed Critical Singapore Lihui Co ltd
Publication of CN110452276A publication Critical patent/CN110452276A/en
Application granted granted Critical
Publication of CN110452276B publication Critical patent/CN110452276B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

An extract of strawberry plant, its extraction method and its novel application are provided. The extraction method comprises the steps of dark culturing strawberry plants in a period from a flowering stage to a primary fruit stage, harvesting the strawberry plants by taking green-white, white or white-red strawberry fruits as a standard, and extracting the strawberry plants by ethanol to obtain strawberry plant extracts. The invention also relates to the use of an extract of strawberry plants for the manufacture of a composition for inhibiting the secretion of cell pro-inflammatory mediators.

Description

Strawberry plant extract, extraction method and application thereof in immunoregulation and anti-inflammation
Technical Field
The present invention relates to a strawberry plant extract, and in particular to a strawberry plant extract combined with the inhibition zone of NF- κB protein and the use thereof for immunoregulation and anti-inflammation.
Background
"phytochemicals" are organic chemicals which are produced during plant growth and have a specific effect on human health, and these organic chemicals can be separated and purified by a certain means and used for food, medical treatment and other purposes.
In the past, plants have been known only as the main source of human foods, and general plant foods contain carbohydrates, vitamins, trace elements and other nutrients, while plants also contain other compounds that have a particular effect on human health are known only poorly. The phytochemicals may be collectively referred to as "phytochemicals" and each plant resembles a small biochemical plant. For example, only tomatoes that are commonly consumed contain up to 1 ten thousand phytochemicals, and their separation by a certain means is equivalent to 1 ten thousand new "drugs".
NF-. Kappa.B (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex that controls the transcription of DNA within biological cells, and its presence can be found in all animal cells, and its operation is to cope with cellular stimulation by factors such as stress, cytokines, free radicals, ultraviolet radiation, oxidized low density proteins, antigens of bacteria or viruses, and is associated with the regulation of the body's immune system. Abnormal regulation of NF- κb is associated with cancer, inflammation, autoimmune diseases, sepsis, and viral infection.
A number of drugs are currently being shown to inhibit the early inflammatory response of cancer by affecting NF- κB activity. For example, NF- κb is inhibited by aspirin (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs) and blocks the progression of part of the tumor, especially colorectal cancer. Other steroid therapies, such as those used to treat intestinal inflammation and asthma, are also most likely to be achieved by inhibiting NF- κB activity. In addition, chemical agents, 5-FU (Fluorouracil), which have been commonly used in the past for patients with head and neck cancer, have also been shown to be associated with the inhibition of NF- κB expression.
Thus, NF- κB can be used as a selective recognition standard for ameliorating a variety of inflammatory diseases, including arthritis, asthma and autoimmune diseases, and in the past medical research reports, efforts have been made to find compounds that interfere with the NF- κB regulatory pathway in a manner that results from drug synthesis.
Disclosure of Invention
In view of the above, an object of the present invention is to provide a method for extracting strawberry plant extract, which facilitates the expression of plant compounds by controlling the environmental conditions of plant growth, and extracts strawberry plant extract containing high amounts of plant compounds.
According to one embodiment of the present invention, there is provided a method for extracting an extract of strawberry plants, comprising harvesting whole plants and extracting with ethanol after harvesting, wherein the strawberry fruits are green-white, white or white-red as a harvesting standard, after dark cultivation (darkly incubation) for 4-7 days during the period from the initial flowering period (anthesis) to the initial fruiting period (first harvest).
According to one example of this embodiment, the strawberry plant comprises 60% -95% of the sum of strawberry roots, stems, leaves, calyx, and 5% -40% of strawberry fruits.
According to one example of this embodiment, wherein the ethanol is 95% ethanol.
An example according to this embodiment, wherein the strawberry plant is selected from the group consisting of Fragaria x ananass, fragaria hayatai Makino, fragaria chiloensis, fragaria nilgerrensis, fragaria nipponica, fragaria nilgerrensis Schlecht, fragaria virginiana, fragaria x vesca, fragaria iturupensis Staudt and any combination thereof.
According to one example of this embodiment, wherein the strawberry plant extract comprises compound (a) which binds to the inhibition zone of NF- κb:
Figure BDA0002050700790000031
it is another object of the present invention to provide a use of an extract of a strawberry plant, including a use for preparing a pharmaceutical product, a food or a nutritional supplement having a composition for immunomodulation and inhibition of secretion of cell pro-inflammatory mediators.
According to one embodiment of the present invention, there is provided a composition comprising a strawberry plant extract and, optionally, an edible carrier.
According to an example of the present embodiment, the food composition is a health food, a functional food, a nutritional supplement food or a special nutritional food.
Examples according to this embodiment wherein the food composition is in the form of a beverage, lozenge, pill, capsule, lozenge, granule, powder, suspension, sachet, pastille, candy, stick or syrup.
Drawings
The above and other objects, features, advantages and embodiments of the present invention will become more apparent by reading the following description of the accompanying drawings in which:
FIG. 1 is a graph of the results of a Fischer's Cross-Validation test in accordance with one embodiment of the present invention;
FIG. 2 is a contour message pattern of NF- κB three-dimensional space;
FIG. 3 is a two-dimensional planar state diagram of the inhibition compound KSA binding to NF-. Kappa.B proteins;
FIG. 4 is the result of the overlap of the decrystallized and chimeric configurations of the inhibitory compound KSA;
FIGS. 5 (a) and 5 (B) are a three-dimensional and a two-dimensional state diagram, respectively, of the chimeric plant compound of formula (1) and NF- κB protein of the present invention;
FIGS. 6 (a) and 6 (B) are a three-dimensional and a two-dimensional state diagram, respectively, of the chimeric plant compound of formula (2) and NF- κB protein of the present invention;
FIGS. 7 (a) and 7 (B) are a three-dimensional and a two-dimensional state diagram, respectively, of the chimeric plant compound of formula (3) of the present invention with NF- κB protein;
FIGS. 8 (a) and 8 (B) are a three-dimensional and a two-dimensional state diagram, respectively, of the chimeric plant compound of formula (4) and NF- κB protein of the present invention; and
FIGS. 9 (a) and 9 (B) are a three-dimensional and a two-dimensional state diagram of the chimeric plant compound of formula (5) and NF- κB protein of the present invention, respectively.
FIGS. 10 (A) and (B) are the results of immune cell anti-inflammatory tests performed on strawberry plant extracts (SBEs) under different maturation conditions according to the invention.
FIGS. 11 (A), (B) and (C) are the results of immune cell anti-inflammatory tests performed on strawberry plant extracts (SBE) under different extraction conditions according to the invention.
FIG. 12 is a flow chart for the separation of strawberry plant extracts.
FIG. 13 is a high performance liquid chromatography of a sample of n-butanol layer extract of strawberry plant extract.
Detailed Description
The present invention utilizes Computer-aided drug design (Computer-Aided Drug Design, CADD) to screen the agricultural plant compound database for plant compounds that bind to NF- κb inhibitory regions, which are used to prepare pharmaceutical products, foods or nutritional supplements that enhance immunomodulatory and/or anti-inflammatory activity via plant extraction techniques. Therefore, the drug design is combined with the upstream agricultural industry, and the agricultural economic value is further improved.
According to one embodiment of the present invention, the following formula (1), formula (2), formula (3), formula (4), or formula (5) compounds are screened out from agricultural plant compounds using a computer-aided drug design:
Figure BDA0002050700790000051
/>
Figure BDA0002050700790000052
wherein the plant source is Strawberry (Strawberry), pear (Pyrus bourgeana), boschniakia rossica (Boschniakia rossica), siraitia grosvenorii (Siraitia grosvenorii), or sweet pepper (sweet pepper fruits of Capsicum annuum L).
According to one embodiment of the invention, the above phytochemicals may be formed into a composition with an optional edible carrier. The composition may be in the form of a beverage, lozenge, pill, capsule, lozenge, granule, powder, suspension, sachet, pastille, candy, stick or syrup.
According to another embodiment of the present invention, the above plant compounds and compositions may be used for the preparation of pharmaceutical products, foods or nutritional supplements that enhance immunomodulating and/or anti-inflammatory activity.
The nutritional supplements of the present invention include food supplements and functional foods. "food supplement" refers to a product made from a compound used in normal food products, but which is a lozenge, powder, capsule, medicament or any other form that is not normally associated with nourishment and has a beneficial effect on human health. A "functional food" is a nourishment that also has a beneficial effect on the health of humans, e.g., under the trade name nucleic class TM Is a nutritional supplement of (a).
The composition according to the invention is a dietary supplement which may be mixed with a suitable drinkable liquid, such as water, yogurt, milk or juice, or may be mixed with a solid or liquid food product. The dietary supplement may be in the form of lozenges, pills, capsules, lozenges, granules, powders, suspensions, sachets, pastilles, candies, sticks, syrups and corresponding administration forms, typically in unit dosage form. Preferably, the dietary supplement comprising the composition of the present invention is administered in the form of lozenges, troches (lozenges), capsules or powders, manufactured in a conventional manner for preparing dietary supplements.
Experimental example 1-1 screening System construction
According to the natural plant architecture (Natural Product Index Approach, NPIA) procedure, a screening system with high accuracy was established for subsequent plant compound screening. One of the 6000 training sets was found and Fischer's Cross-Validation was used to determine if the training set had sufficient confidence levels.
In the detection, the molecular structures in the training group are randomly distributed with biological activity to generate pharmacophores, the execution times are 99 times, and whether the pharmacophores generated in the random recombination are identical with the data generated in the original process is observed. Referring to FIG. 1, which shows the results of the Fischer's Cross-Validation test performed for the last 10 of 99 times, it was found that none of the results generated using the random methods (random 01-random 10) reached the same data as the original training set (cost), indicating that the selected training set had a high level of confidence and could not be randomly generated.
Then, using the generated pharmacophore as superposition condition, superposing the three-dimensional configuration of the training compound by using the chemical characteristics of the pharmacophore in the three-dimensional space as reference point, adding Gasteiger-Huckel charges to the superposed training compound, and applying CHARMM (Chemistry at Harvard Macromolecular Mechanics) force field to obtain sp 3 Mixed carbon atoms (sp 3 Hybridized carbon atom) as probes in the stereo space to calculate the NF- κB profile information (Contour Information).
FIG. 2 is a contour message pattern of NF- κB three-dimensional space. Through calculation, r is obtained 2 ncv The coefficient was 0.99, the estimated standard error (standard error of the estimate, SEE) was 0.16, and the composition of the nf- κb profile message was three-dimensional (stereo), electrostatic (electrostatic), hydrophobic (hydro-binary), hydrogen donor (hydro-generator), hydrogen acceptor (hydrogen acceptor), in the proportions 0.16, 0.18, 0.20, 0.21, 0.25, as shown in fig. 2.
Experimental examples 1-2 phytochemicals search rope
And respectively generating three-dimensional configurations of all plant compounds in the agricultural plant compound database, superposing each plant compound on the pharmacophore, and recording the superposed three-dimensional configurations. Next, the biological activity of each of the superimposed plant compounds is predicted by chemical profile to find the plant compounds of the following formulas (1), (2), (3), (4) and (5):
Figure BDA0002050700790000071
Figure BDA0002050700790000081
Figure BDA0002050700790000082
wherein the plant source is strawberry, fructus Siraitiae Grosvenorii, herba Boschniakiae Rossicae, fructus Pyri, or fructus Zanthoxyli.
Experimental examples 1-3 chimeric parameter settings and test
The protein structure of NF- κB adopts a protein crystal structure published in the journal of biochemistry (Journal of Biological Chemistry) in 2013, which has the code of 4KIK in protein database (Protein Data Bank) and resolution of
Figure BDA0002050700790000083
NF-. Kappa.B is a trimeric structure which contains one of the inhibiting compounds KSA. FIG. 3 is a two-dimensional planar state diagram of the inhibition of binding of the compound KSA to the NF- κB protein, from which the amino acid information of the NF- κB inhibition region is known.
The structure prediction after the combination of NF- κB and plant compound was performed using CHARMm-based molecular dynamics docking calculation method. In order to confirm that the calculation method can effectively embed the plant compound into the NF- κB protein structure, and make the three-dimensional configuration after embedding approach to the actual decrystallization configuration, the inhibition compound KSA is utilized to find out the embedding parameters. FIG. 4 shows the overlapping results of the decrystallization configuration and the chimeric configuration (green) of the inhibition compound KSA, with a root-mean-square error (RMSD) of 0, showing that the chimeric parameters found effectively mimic the decrystallization of the compound to be embedded in the NF-B protein structure.
Fig. 5a, 5B to 9a, 9B are three-dimensional and two-dimensional state diagrams of the plant compounds of formula (1), formula (2), formula (3), formula (4), and formula (5) according to the present invention, respectively, chimeric NF-B proteins. The plant compounds of the present invention are shown in the figures as formula (1), formula (2), formula (3), formula (4) and formula (5), which are chimeric in NF- κB protein and interact with amino acids, and all conform to the spatial size of the inhibition region of NF- κB protein, so that the inhibition of NF- κB protein activity can be achieved to enhance immunoregulatory and/or anti-inflammatory activity.
Experimental example 2-1 extraction of plant Compound
The compound (A) screened from the plant compounds is designed by using the computer-aided drugs, and after the comparison of the database, the proper plants are obtained for extraction so as to actually measure the activity:
Figure BDA0002050700790000091
the plant compound source thereof may be strawberry, the strawberry variety may include, but is not limited to, fragaria x ananass, fragaria hayatai Makino, fragaria chiloensis, fragaria nilgerrensis, fragaria nipponica, fragaria nilgerrensis Schlecht, fragaria virginiana, fragaria x vesca, or Fragaria iturupensis Staudt, as searched by database.
The compound (a) is a terpene compound (Terpenes), and according to the study of Kim et al (2013), the volatile terpene compound contained in strawberry contains monoterpenes (monoterpenes), sesquiterpenes (sesterpenoids), diterpenes (diterpenes), triterpenes (Triterpenes) and the like, and is widely present in various parts of strawberry plants, especially the most green parts such as roots, stems, leaves, calyx and the like.
The strawberry variety Fragaria x ananass is selected as an example, the whole plant is extracted by different solvents, and after the extraction rate is calculated, 95% ethanol is selected as the optimal solvent, and water is used as a control group for extraction. The 95% ethanol was heated by a hot reflux extraction device to extract a sample, and the sample was heated for 3 hours from the start of boiling, and the heated container was taken out and allowed to stand for cooling. After standing and cooling, the sample waste residue is preliminarily filtered by using a screen. The sample was then filtered through a buchner funnel and the liquid after filtration was kept well at 4 ℃ until it was concentrated. Concentrating (sample heating temperature is 53-56 ℃ and vacuumizing) by using a reduced pressure concentration system, uniformly mixing all concentrated thick liquid, performing vacuum freeze drying, and scraping a dried sample.
Experimental example 2-2 strawberry plant extracts for immune cell anti-inflammatory test (I)
Since the compound of formula 1 belongs to a volatile terpenoid compound, plays a role in providing a special flavor during the strawberry ripening process, and it is known that the ripening of fruits under different environments may induce the gene expression of plant compounds to generate different flavors and appearances, the difference of immune cell anti-inflammatory effects of environmental factors during the strawberry ripening process on strawberry plant extracts is observed during the period from the initial flowering period (anthesis) to the initial fruiting period (first harvest) under different temperatures and photoperiod as test conditions.
In the present description, the term "flowering stage" refers to the period from the start of the flowering period to the complete opening and functioning of the flowers; the term "initial stage" (first harvest stage) refers to the initial stage of the strawberry fruit growing to full ripening.
Samples were grown for 2-7 days at 25℃and 15℃under natural light cycle (16/8, natural light) and dark room (dark) respectively, and whole plants were harvested and extracted with 95% ethanol and/or water.
The strawberry plant extract (SBE) extracted with 95% ethanol was initially tested at a concentration of 50. Mu.g/ml in LPS stimulation mode with murine peripheral macrophage cell line RAW264.7, lung macrophage cell line MHS and neuromacrophage cell line BV 2. LPS induced release of stimulated NO expression and the cell culture fluid stimulated by LPS was analyzed for NO (nitrite/nitrite) production.
FIG. 10 is the results of immune cell anti-inflammatory tests performed on strawberry plant extracts (SBEs) under different maturation conditions according to the invention. FIG. 10 (A) shows the results of an immune cell anti-inflammatory test of strawberry plant extract (SBE) of plants harvested after 4 or 7 days of culture at 25℃and 15℃in natural photoperiod (16/8, natural light); FIG. 10 (B) shows the results of an immune cell anti-inflammatory test of strawberry plant extract (SBE) obtained after culturing for 4 or 7 days in a dark room (dark room) at 25℃and 15 ℃. The strawberry plants described in all embodiments of the invention comprise whole plants, and the total of the strawberry roots, stems and leaves accounts for 60% -95% and the strawberry fruits accounts for 5% -40%.
As a result, as shown in FIGS. 10 (A) and (B), the strawberry plant extract (SBE) obtained after 4 or 7 days of treatment in the dark (dark) at 25℃and 15℃had significantly better anti-inflammatory effect than the strawberry plant extract (SBE) obtained after 4 or 7 days of cultivation in the natural photoperiod (16/8, natural light) at 25℃and 15 ℃.
Thus, according to the embodiment of the invention, the strawberry plant extract (SBE) with better anti-inflammatory effect is obtained by dark culturing for 4-7 days from the initial flowering period to the initial fruiting period, and the temperature is controlled below 15-25 ℃, so that the anti-inflammatory effect of the strawberry plant extract (SBE) can be promoted, wherein the strawberry fruits ripened by dark culturing are green-white, white or white-red. According to one embodiment of the present invention, the strawberry plant extract (SBE) is dark cultured for 4 days from the initial flowering period to the initial fruiting period, and the temperature is controlled below 15 ℃, so as to promote the anti-inflammatory effect of the strawberry plant extract (SBE), wherein the strawberry fruits ripened by dark culture are green-white, white or white-red.
Experimental examples 2-3 strawberry plant extracts were tested for immune cell anti-inflammatory assay (II)
According to the above, strawberry plants were treated in darkroom (dark) at 15deg.C for 4-7 days, and then the whole plants were harvested and extracted with the strawberry fruits showing green-white, white or white-red as harvesting standard. Wherein 95% ethanol (95% EtOH) was used as the experimental group, and water (H 2 O) is a control group, and the effect of inhibiting secretion of cell pro-inflammatory mediators is observed by treating murine peripheral macrophage cell line RAW264.7, lung macrophage cell line MHS and neuromacrophage cell line BV2 cell line with 95% ethanol extract (10 ug/ml,50ug/ml,100 ug/ml) of strawberry plant and water extract (10 ug/ml,50ug/ml,100 ug/ml) of strawberry plant respectively.
FIG. 11 shows the results of immune cell anti-inflammatory tests performed on strawberry plant extracts (SBEs) under different extraction conditions according to the invention. FIG. 11 (A) shows the results of LPS stimulation mode of cell line RAW 264.7; FIG. 11 (B) shows the results of LPS stimulation with cell line MHS; FIG. 11 (C) shows the results of LPS stimulation mode of cell line BV 2.
As shown in FIG. 11 (A), the cell line RAW264.7 was treated with a 95% ethanol extract at a concentration of 50,100 ug/ml, which had the effect of reducing the NO expression stimulated by LPS and exhibited a dose-dependency; whereas the cell line RAW264.7 treated with the aqueous extract of strawberry plants had a less pronounced effect except in the high dose (100 ug/ml) group.
As shown in FIG. 11 (B), treatment of cell line MHS with 95% ethanol extract at a concentration of 10, 50, 100ug/ml has the effect of reducing the NO expression stimulated by LPS, and exhibits dose dependency; whereas the effect is not obvious for the cell line MHS treated with the aqueous extract of strawberry plants.
Referring again to FIG. 11 (C), treatment of cell line BV2 with 95% ethanol extract at a concentration of 10, 50, 100ug/ml significantly reduced LPS-stimulated NO expression and exhibited dose dependence; the cell strain MHS treated by the strawberry plant water extract has the effect of inhibiting the secretion of cell pro-inflammatory mediators at the concentration of 10, 50 and 100 ug/ml.
Therefore, according to the embodiment of the invention, the strawberry plant extract (SBE) with better anti-inflammatory effect is obtained, the temperature is controlled to be below 15 ℃ to 25 ℃ in the period from the initial flowering period to the initial fruiting period, and the strawberry plant extract (SBE) is harvested after dark culture is carried out for 4 to 7 days and then extracted by 95% ethanol, so that the anti-inflammatory effect of the strawberry plant extract (SBE) can be promoted. According to one embodiment of the present invention, the strawberry plant extract (SBE) with better anti-inflammatory effect is prepared by dark culturing for 4 days at a temperature below 15 ℃ during the period from the initial flowering period to the initial fruiting period, and extracting with 95% ethanol.
Experimental example 3 purification and quantitative analysis of active ingredients of strawberry plant extracts
FIG. 12 is a flow chart for the separation of strawberry plant extracts. The ethanol extract of strawberry plants was separated into ethyl acetate layer, n-butanol layer and water layer using partition extraction separation method.
FIG. 13 is a high performance liquid chromatography of a sample of n-butanol layer extract of strawberry plant extract. Sample preparation 10mg of n-butanol layer extract of strawberry plants was taken, 1ml of dimethyl sulfoxide (DMSO) was added, filtered through a 0.45 μm syringe filter and refrigerated at 4℃for further use. The compound of Formula (1) was further purified by high performance liquid chromatography (high performance liquid chromatography; HPLC) for component purification and structural identification. Using a C-18 liquid chromatography column (Phenomenex Luna C-18 column), the Mobile phase (Mobile phase) was Water/Acetonitrile=0 min:93/7,3min:93/7,70min:83/17,75 min:38/17), the Flow rate (Flow rate) was 1ml/min, and the HPLC-UV detection wavelength was 227nm. The structure of compound (a) is identified in table one below. Powder;1H-NMR (400 MHz, CD3 OD) and 13C-NMR (100 MHz, CD3 OD).
TABLE I Structure identification of Compound (A)
Figure BDA0002050700790000131
Figure BDA0002050700790000141
According to the above, the ethanol extract of strawberry plants can be purified to obtain the compound (A), and the compound (A) is embedded in NF- κB protein to interact with amino acid, which accords with the space size of the NF- κB protein inhibition region, and can achieve the effect of enhancing the immunoregulation and/or anti-inflammatory activity by inhibiting the NF- κB protein activity.
In accordance with one embodiment of the present invention, the strawberry plant extract may be formed into a composition with an optional edible carrier. The composition may be in the form of a beverage, lozenge, pill, capsule, lozenge, granule, powder, suspension, sachet, pastille, candy, stick or syrup.
According to another embodiment of the present invention, the above plant compounds and compositions may be used for the preparation of pharmaceutical products, foods or nutritional supplements that enhance immunomodulating and/or anti-inflammatory activity. The nutritional supplements of the present invention include food supplements and functional foods. "food supplement" refers to a product made from a compound used in normal food products, but which is a lozenge, powder, capsule, medicament or any other form that is not normally associated with nourishment and has a beneficial effect on human health. A "functional food" is a nourishment which also has a beneficial effect on the health of humans, e.g., under the trade name nucleic class TM Is of (2)And (5) a nutrient supplement.
The composition according to the invention is a dietary supplement which may be mixed with a suitable drinkable liquid, such as water, yogurt, milk or juice, or with a solid or liquid food product. The dietary supplement may be in the form of lozenges, pills, capsules, lozenges, granules, powders, suspensions, sachets, pastilles, candies, sticks, syrups and corresponding administration forms, typically in unit dosage form. Preferably, the dietary supplement comprising the composition of the present invention is administered in the form of lozenges, troches (lozenges), capsules or powders, manufactured in a conventional manner for preparing dietary supplements.
One or more of the above plant compounds may be formed into a composition with an optional edible carrier. The composition may be in the form of a beverage, lozenge, pill, capsule, lozenge, granule, powder, suspension, sachet, pastille, candy, stick or syrup. And further using the above plant compounds or compositions thereof for the preparation of a pharmaceutical product, food or nutritional supplement for enhancing immunomodulatory and/or anti-inflammatory activity.

Claims (2)

1. A method of producing a strawberry plant extract comprising:
dark culturing the strawberry plants in the period from the initial flowering period to the initial fruiting period;
harvesting the strawberry plants, wherein the strawberry fruits are green-white, white or white-red as harvesting standards; and
extracting the strawberry plant with 95% ethanol to obtain the strawberry plant extract, wherein the strawberry plant comprises 60% to 95% of the sum of strawberry roots, stems, leaves, calyx, and 5% to 40% of strawberry fruits;
further comprising performing the dark culture at a temperature below 15 ℃; the dark culture period is from the initial flowering period to the initial fruit period for 4 to 7 days;
the strawberry plant is selected from the group consisting ofFragaria×ananass、Fragaria hayatai Makino、 Fragaria chiloensis、Fragaria nilgerrensis、Fragaria nipponica、Fragaria nilgerrensis Schlecht、Fragaria virginiana、Fragaria×vesca、Fragaria iturupensis StaudtAnd any combination thereof;
the strawberry plant extract contains a compound (A) which can be combined with an inhibition zone of NF- κB:
Figure QLYQS_1
a compound (A).
2. Use of the strawberry plant extract produced by the method of claim 1 for the manufacture of a composition characterized in that: the composition is used for inhibiting secretion of cell pro-inflammatory mediators; the composition is a pharmaceutical composition.
CN201910373148.2A 2018-05-07 2019-05-06 Strawberry plant extract, extraction method and application thereof in immunoregulation and anti-inflammation Active CN110452276B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810428447 2018-05-07
CN2018104284477 2018-05-07

Publications (2)

Publication Number Publication Date
CN110452276A CN110452276A (en) 2019-11-15
CN110452276B true CN110452276B (en) 2023-05-12

Family

ID=68480930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910373148.2A Active CN110452276B (en) 2018-05-07 2019-05-06 Strawberry plant extract, extraction method and application thereof in immunoregulation and anti-inflammation

Country Status (1)

Country Link
CN (1) CN110452276B (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217848A1 (en) * 2002-03-01 2003-09-16 John M. Cassady Compositions of and derived from strawberry and raspberry and therapeutic uses therefor
CN101058594A (en) * 2006-04-21 2007-10-24 中国医学科学院药物研究所 Sarcandra glabra effective constituent, preparation method thereof, medicament composition and use of the same
JP5856728B2 (en) * 2009-07-21 2016-02-10 国立大学法人金沢大学 Composition for oral administration or external use comprising polyphenol, and use thereof
CN102924536A (en) * 2012-11-06 2013-02-13 山东省农业科学院农产品研究所 Preparation method of strawberry polyphenol
WO2014150948A2 (en) * 2013-03-15 2014-09-25 Monsanto Technology Llc Methods for modifying flowering time and seed yield in field crops
US20170224757A1 (en) * 2014-07-22 2017-08-10 Signum Nutralogix, Inc. Natural extracts for modulating pp2a methylation, and providing antioxidant and anti inflammatory activity
CN105165611B (en) * 2015-09-22 2017-04-26 江苏农林职业技术学院 Culturing method for strawberry fruit calluses

Also Published As

Publication number Publication date
CN110452276A (en) 2019-11-15

Similar Documents

Publication Publication Date Title
Bhat et al. Tongkat Ali (Eurycoma longifolia Jack): a review on its ethnobotany and pharmacological importance
CN106456597A (en) Nox inhibitor and NFkB inhibitor containing methoxyflavone
Dixit et al. Medicinal properties of Moringa oleifera: A review
CN102143741A (en) Uses of sesquiterpene derivatives
CA2700236A1 (en) Anticancer composition comprising plant stem cell line derived from taxus cambium or procambium
JP6931930B2 (en) Improved process for producing fucoxanthin and / or polysaccharides from microalgae
KR100896700B1 (en) A.tuberosum Rottl. extract having an activity of activating choline acetyltransferase in brain nerve cells
Anwer et al. Detection of immunoactive insulin in Spirulina
JP2019536798A (en) A health-functional food composition for preventing and ameliorating depression, comprising an extract of shashanbo seeds
KR20210074807A (en) Inflammatin alleviating composition comprising an extract of white opium-free poppy as an effective ingredient
JP5888763B2 (en) Fermented buckwheat extract
CN107822136A (en) A kind of raw-food material and its extracting method containing high content nervonic acid
CN110452276B (en) Strawberry plant extract, extraction method and application thereof in immunoregulation and anti-inflammation
KR101829583B1 (en) Pharmaceutical composition having anti-depressant activity and preparation method using Vaccinium bracteatum Thunb. of the same.
CN107530391A (en) Cooperative compositions for osteoarthritis
JP3911427B2 (en) Novel sesquiterpene compound, production method and composition thereof
JP6436337B2 (en) Quercetin derivative exhibiting elastin producing action and method for producing the same
US11071766B2 (en) Strawberry plant extract and use thereof
TWI711457B (en) Strawberry plant extract, extraction method and novel use thereof
CN105712844A (en) Cadinane sesquiterpene Saliciforliusin A and preparation method and application thereof
KR102501955B1 (en) A composition for immune enhancement comprising benicasa hispida extract
EP1416927A1 (en) Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect
KR101503583B1 (en) Compositions for anti-obesity comprising extract of Vitis amurensis ruprecht
JP2011241225A (en) Method for preparing polyamine composition from plant
KR20160136855A (en) Composition for ameliorating cognitive functions comprising extacts from processed Polygoni Multiflori Radix

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant